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(c) Advance(s) in Knowledge: 
1. Features extracted from breast DCE-MRI data, typically used in CADx, have 
unequal importance according to type (i.e mass or non-mass) 
2. Feature importance analysis revealed that kinetic and textural features have higher 
importance weighting among mass lesions than among non-mass lesions, and 
morphology features have higher importance weighting among non-masses. 
3. A 2-stage cascade classifier performs better than a one-shot classifier. Median 
AUCs are 0.91 for cascading and 0.89 for one-shot, and this difference was 
statistically significant (p-value=0.0027). 
4. The 2-stage cascade classifier decreases the overall misclassification rate by 12%, 
(72/409) missed cases by cascade versus (82/409) missed by one-shot. 
5. Cascade classifier can benefit from designing features accordingly to mass or non-
mass enhancement types. 
 (d) Implication(s) for Patient Care:  
It is important to consider different image features for mass and non-mass lesions when 
interpreting breast MR images. 
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(e) Summary statement:  
We were able to achieve a more accurate classification of malignant vs. benign 
breast lesions (AUC=0.91) by using different features for mass and non-mass 
lesions. 
 
 
Abstract 
Purpose: 
To determine suitable features and optimal classifier design for a computer-aided 
diagnosis (CAD) system to differentiate among mass and non-mass enhancements 
during dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of the 
breast. 
Materials and Methods: 
Histology-proven 280 mass lesions and 129 non-mass lesions from MRI studies were 
retrospectively collected. The institutional research ethics board (REB) approved this 
study and waived informed consent. BIRADS classification of mass and non-mass 
enhancements was obtained from radiology reports. Image data from DCE-MRI was 
extracted and analyzed using feature selection techniques and binary, multiclass and 
cascade classifiers. Performance differences among classifiers were assessed by area 
under the receiver operating characteristic curve (AUC), Sensitivity (Se) and Specificity 
(Sp). Bootstrap cross-validation was used to predict the feature sets and the classifier 
choices with the best discrimination power for the classification task of mass and non-
mass benign and malignant breast lesions. 
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Results: 
A total of 176 features were extracted from the lesion ROI. Feature relevance ranking 
indicated unequal importance of kinetic, texture and morphology features for mass and 
non-mass lesions. Best classifier performance was a 2-stage cascade classifier (mass 
vs. non-mass followed by malignant vs. benign classification), with 0.91 AUC, 95%CI: 
[0.88-0.94] in comparison to one-shot (i.e. all benign vs. malignant classifier) with 0.89 
AUC, 95%CI: [0.85-0.92]. The AUC was 2% higher for cascade (median % difference 
obtained using paired bootstrapped samples) and this was statistically significant (p-
value=0.0027). Our proposed 2-stage cascade classifier decreases the overall 
misclassification rate by 12%, (72/409) missed diagnoses by cascade versus (82/409) 
missed by one-shot. 
Conclusion: 
Optimizing feature selection and training classifiers for mass and non-mass lesions 
separately improves the accuracy of a CAD for breast MRI. By cascading classifiers we 
obtained a significant improvement in performance with respect to a one-shot classifier. 
Our cascaded classifier may provide an advantage for screening of women at high-risk, 
where the ability to diagnose cancers at an early-stage is of primary importance. 
 
Page 3 of 37
Prudential Tower, 800 Boylston Street, 15th Floor, Boston, MA 02199
RADIOLOGY
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Introduction 
In the context of breast cancer screening for women at high-risk, the ability to detect 
cancers at early stages while they are associated with a good prognosis and when 
treatment is most effective is of primary importance. Dynamic contrast-enhanced 
magnetic resonance imaging (DCE-MRI) of the breast has been shown to have higher 
sensitivity than mammography and ultrasound for women at increased risk of breast 
cancer and is increasingly being used for screening purposes (1). Computer-aided 
diagnosis has the potential to improve observer reproducibility in DCE-MRI by carrying 
out quantitative analysis of contrast uptake and lesion morphology. According to the BI-
RADS lexicon, enhancement patterns can be classified as mass, non-mass or foci 
(<5mm) enhancing lesions. Previous work has investigated different automatically 
extracted features to quantify the observation that malignant masses take up contrast in 
a more heterogeneous pattern, have less defined boundaries and are more irregularly 
shaped than benign masses (2–5). Nonetheless, there have been relatively few studies 
that investigate suitable features and optimal CAD classifiers for non-mass lesions 
compared to studies carried out on mass lesions. A pilot study by Jansen et al. (6) 
showed that kinetic analysis has discriminative power to differentiate between benign 
and malignant mass lesions effectively but not between benign and malignant non-mass 
lesions. However, another study showed that, unlike visual assessment of kinetic 
descriptors, computer-aided analysis of voxel-wise enhancement kinetics was able to 
demonstrate significant differences between the enhancement patterns of benign and 
malignant non-mass lesions (7). One type of malignant lesion that commonly presents 
as non-mass enhancement is ductal carcinoma in-situ (DCIS). DCIS exhibits high 
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variability in the distribution of initial rise and delayed phase of enhancement (8,9). In 
pure DCIS, malignant neoplastic ductal epithelial cells remain confined inside the 
mammary ducts without invading through the ductal basement membrane. Unlike 
invasive carcinomas, which exhibit rapid perfusion and washout of contrast agent due to 
leaky angiogenic vasculature, in in-situ carcinomas contrast agent perfusion rates 
increase as a lesion progresses from in-situ to invasive and microvessel density plays a 
key role (10). 
Therefore, since the physiological basis of enhancement is highly variable between 
mass and non-mass lesions, when designing a CAD for breast MRI screening it may be 
more effective to optimize classifiers for mass and non-mass lesions separately to 
improve the accuracy of CAD. The purpose of this study is to determine suitable 
features and optimal classifier design for a computer-aided diagnosis (CAD) system to 
differentiate among mass and non-mass enhancements during dynamic contrast-
enhanced magnetic resonance imaging (DCE-MRI) of the breast. 
Materials and Methods: 
Breast MRI datasets: 
Breast MRI studies were selected from our research database which links clinical 
information, radiological reports and pathology reports to MRI DICOM images (11); the 
collection of this data and its use in CAD research has been approved by our 
institutional review board. BIRADS classification of mass and non-mass lesions was 
obtained from the radiological report. In addition, we collected BIRADS lexicon 
descriptors of masses such as shape, margin, and internal enhancement. For non-
masses, BIRADS lexicon descriptors collected included type of enhancement and 
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internal characteristics of enhancement. All patients underwent bilateral DCE-MRI 
between 2001 and 2013 at Sunnybrook Health Sciences Centre on a 1.5-T magnet 
(Signa, General Electric Medical Systems, Milwaukee, WI) using a bolus injection of 0.1 
mmol/kg of Gadolinium contrast agent (Omniscan, GE Healthcare, Oakville, ON). 
Imaging protocol at our institution includes sagittal bilateral DCE-MRI scans with 1 pre-
contrast and 4 post-contrast scans, taken approximately 2 to 3 minutes apart. Imaging 
protocols included in this study are summarized in the appendix. 
In the time interval of this study, we identified retrospectively 1005 patients with 2648 
DCE-MRI studies. 710 patients had lesions BIRADS 1, 2 or 3 and no lesions with 
BIRADS>=3 within two years after the initial exam (Benign by assumption). 295 patients 
had lesions BIRADS>=3 that were recalled for biopsy, and the diagnostic histopathology 
procedure had to be done within three months after imaging. We excluded 55 patients 
for the following reasons: 40 had previous breast cancer, 3 due to difficulty in locating 
the lesion reported, and in 12 patients images were not available. We were able to 
select 240 patients (mean age 48 years, age range 29-85 years) with 409 breast lesions 
BIRADS>=3 in DCE-MRI studies performed prior to biopsy. Ground truth histopathology 
was obtained from either core needle biopsy (n=221), vacuum assisted biopsy (n=92), 
fine needle aspiration (n=17) or surgical excision by lumpectomy (n=63) from the 
location of the lesion.  A total of 280 histology proven mass lesions (136 benign, 144 
malignant), and 129 histology proven non-mass lesions (65 benign, 64 malignant), were 
included in the study. Malignant pathologies included in-situ ductal (n=56), and invasive 
ductal (n=125) as well as 22 invasive lobular carcinomas. Benign pathologies included 
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33 fibroadenomas, 12 duct papillomas, 39 fibrocystic disease cases (table 1). Reasons 
for breast MRI examination are listed on the appendix (online only).  
Lesion segmentations: 
Registration was not performed prior to segmentation of lesions, as a visual assessment 
of the subtraction images was carried out and it was determined that none of the 
datasets were corrupted by patient motion. Each lesion was segmented by CGO 
(graduate student with 5 years experience in analysis of breast MRI) using a semi-
automated 3D 4-connected-component flood fill thresholding technique; the location 
quadrant and clock position from the radiology report was used to initialize the region of 
interest. We confirmed that the extent of the segmented lesions was in agreement with 
the manual 2D annotations made by the reporting radiologist, where these annotations 
were available. Some woman had multiple lesions in the same imaging study, mostly in 
opposite breasts. In cases where a single lesion consisted on a cluster of 
segmentations, the cluster was treated as a single lesion. We verified that the 
segmented regions were included within the extent of the lesion reported by the 
radiologist. A total of 131 annotations (109 calipers, 12 ellipses, 10 line arrows) were 
available for verification of the agreement of our semi-automated lesion segmentation 
with the lesion localization and the extent indicated by the radiologist’s annotations. The 
in-plane segmented lesion diameter at the same angle of the caliper mark was 
compared with the annotated lesion extent to obtain a measurement of agreement.  
Lesion descriptors: 
Kinetic, morphology and texture features were used to characterize the likelihood of 
malignancy, while a set of cluster-based signal intensity and dispersion features were 
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added for the discrimination between mass and non-mass lesions. Kinetic features were 
measured based on the average DCE-MRI signal intensity in the segmented volume of 
interest (VOI), extracted from both the boundary and internal pixels of the segmented 
VOI, excluding background pixels. A 3 parameter empirical mathematical model 
proposed in (12) was used to fit the contrast enhancement profile: 
, where  is the upper limit of the signal intensity,  is 
the rate of initial signal increase, and  is the rate of signal decrease during 
washout. The goodness of fit parameter R2 was calculated for each lesion. In addition, a 
total of 5 empirical mathematical model derived parameters were extracted. 3D 
morphologic features such as circularity and irregularity of shape were extracted from 
the 3D surface area and 3D volume. Margin sharpness was extracted using pixels at 
the boundary of the lesion. Since for non-mass lesions there are no clear boundaries, 
these shape features were extracted from the largest connected component. All textural 
features were based on the grey-level co-occurrence matrix (6), which measures the 
heterogeneity of contrast uptake and the degree of local texture variations from pixels 
inside the VOI with 1-pixel separation at 4 different orientations. A total of 176 features 
were extracted from the VOIs. The pool of lesion descriptors can be summarized in the 
following categories: 
Dynamic empirical mathematical model derived: Consisting of total of 3 primary 
and 5 model derived features. These features capture the kinetic characteristics of 
enhancement (e.g rates of initial uptake and subsequent washout of contrast agent 
the time-to-peak, and curvature-at-peak enhancement). 
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Dynamic enhancement-kinetics: Related to the temporal relative signal intensity 
within the lesion. Features in this category describe the characteristics of the 
average enhancement over the lesion at each post contrast time point (e.g 
maximum contrast uptake, post-contrast time point of maximum contrast uptake, and 
washout rate), as described in the literature (4). 
Dynamic enhancement-variance: Reflect the heterogeneity of enhancement 
across the lesion. Features include the maximum variation of enhancement, the 
post-contrast time at which the maximum variance occurs, and variance rates, as 
described in the literature (4).  
Morphologic features: Based on 3D morphology. A total of 8 features describing 
the circularity, irregularity, and margin sharpness (7) to quantify spiculation of a 
lesion (4). In addition, radial gradient analysis features (13) indicate how well 
structures extend in a radial pattern. 
Texture features: These features are based on the co-occurrence of voxel-pair of 
gray levels i and j whose spatial locations are a vector d apart. From the matrix of 
co-occurrences, different statistical measures can be derived (e.g energy, contrast, 
similarity, correlation) 
Enhancement-dispersion features: We proposed enhancement-dispersion 
features based on the distribution and clustering of enhancements measured at 
each of the post-contrast time points. This allows for capturing the differences 
between high proximity seen in masses, and low proximity or dispersion found in 
non-masses. We used 20-clusters based on k-nearest neighbors per lesion to 
cluster enhancements and produce a total of 80 relative signal enhancement 
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features (20 DCE relative signal enhancement features per each of the 4 post-
contrast scans). Dispersion was computed by measuring cluster distances from the 
lesion center and normalizing by lesion diameter. A total of 20 dispersion samples 
per lesion were used. Dispersion features were only used with the purpose of 
discriminating dispersion patterns between mass or non-mass lesions, but were not 
added to the remainder of the classifiers, since dispersion is not intended as a 
discriminative feature of malignancy. 
Feature Relevance and optimal subset selection: 
Relevant and irrelevant features among mass and non-mass lesions groups were 
determined using feature importance rankings with random forests (14,15). Unlike other 
“black-box” classifiers, random forests can be interrogated at each of the terminal nodes 
to identify the most discriminant features. A measure of feature importance can be 
obtained as the loss of accuracy for discriminating between benign and malignant cases 
by the introduction of random permutations on feature values, in which case the feature 
is known as a “shadow feature”. Shadow features have low information content and 
their performance is no better than a random guess. In this sense, features that have 
significantly worse importance than shadow features are deemed irrelevant, while 
features that performed significantly better are considered relevant. Tentative features 
are those that performed better but without a statistically significant difference from 
shadow features. If scores from tree to tree are assumed independent, then raw scores 
can be divided by the standard error to obtain a z-score for each feature. Comparison of 
z-scores between mass and non-mass lesion groups was performed to determine 
whether there was a significant difference in relevance for each feature. Statistical 
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differences between sampled z-scores over rounds of feature relevance testing, using 
two-sided t-test with p-values < 0.001 were considered statistically different. Optimal 
features were selected to train all classifiers and consisted of relevant and tentative 
features. 
Training and comparison of classifier designs: 
After optimal subset feature selection, random forest classifiers were trained under 
three different designs:  
a) Binary one-shot: Refers to the task of training a classifier to discriminate between all 
malignant vs all benign, without an explicit differentiation of mass and non-mass lesions.  
b) Multi-class: Multi-class classifiers refer to the discrimination of more than 2 different 
classes. In this work, a 4-class classifier was trained to discriminate between mass 
malignant vs. mass benign vs. non-mass malignant vs. non-mass benign.  
c) Cascade classifier: Our cascade classifier differentiates among the same number of 
classes as the multi-class, but consists of 2 stages of sequential binary classification. 
The first stage separates between mass and non-mass classes while the second stage 
differentiates between malignant and benign cases. The cascade is made up of 3 
separately trained binary classifiers. For the cascade evaluation, cases fed to the 
second stage classifier (one for masses, one for non-masses) are based on the 
prediction of the first stage (classifier for differentiating between masses and non-
masses). Independently of the design scheme, during random forest training, a set of 
ntreeT  classification trees are grown with individual N-bootstrap samples from the 
training data (sample size N). For each node, 
trym
 < M (total number of features) are 
selected at random, and the best split possible out of the information content of all 
trym
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features is chosen (16). Both, ntreeT  and trym  parameters were tuned using 10 
iterations of cross-validation. 
Assessing classifier performance and generalization: 
Random forests combine multiple decision trees, where each tree stratifies the feature 
space into a number of simple non-overlapping regions that maximize classification 
accuracy. It is important to estimate the true error rate and generalization ability. K-fold 
cross-validation was used to estimate prediction error with 10 folds of stratified sampling 
within each class so that the overall class distribution is preserved. Under this setting, 
9/10 of the data at each cross validation run is used for feature selection, RF parameter 
tuning and model training and the remainder 1/10 is used as a hold-out independent 
test set for evaluating final model performance. Classifier performance was tested using 
AUC ROC, Sensitivity and Specificity. We compared AUC differences among classifier 
schemes using resampling based p-values (17). We also analyzed the misclassification 
rate of classifier designs. By comparing if there is any significant decrease in error for 
classifiers trained under a particular scheme, we could predict the features sets and the 
classifier design with the best performance for discriminating between benign and 
malignant lesions. Once cross-validation training was completed, we combined the 
different groups of tree classifiers from all cross validation runs with the lowest 
generalization error, defined here as the ones that performed significantly better than 
AUC>80%, to produce the final classifiers. Cascading performance was estimated by 
pooling the performance of stage 1 (mass vs. non-mass) and stage 2 (benign vs. 
malignant) classifiers. A clear advantage of cascading over one-shot classifiers can be 
demonstrated for cases that are incorrectly classified by one-shot classifier, while 
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correctly classified by the cascade classifier. We looked at all misclassified instances 
using the final ensembles for cascade and one-shot designs. Predictions that agreed 
with the lesion label (e.g benign or malignant) were correct classifications, while 
predictions that disagreed with the label, were misclassifications. 
  
 
Results 
Breast MRI datasets and lesion segmentation  
Examples of segmentation results are shown in (Fig. 1, 2) for an invasive cancer 
presenting as mass enhancement and a DCIS presenting as a non-mass enhancement 
with ductal distribution. Based on caliper annotations, the median lesion diameter was 
8.8 mm, and lesion diameters ranged from 3 mm to 81 mm. The bias of the mean 
difference in segmented lesion diameter compared to the caliper marks of lesion 
diameters was -5.3 mm with a 95%CI of -6.7 to -3.8 mm. Analysis of Breast MRI 
BIRADS lexicon data from radiology reports revealed that of the 136 benign mass 
lesions, MRI characteristics of the overall shape of the enhancement spanned 10 
irregular, 22 lobular, 18 oval, 11 round and 75 not specified. Similarly, for the 144 
malignant masses, descriptors of the border of mass enhancement included 29 
spiculated, 15 irregular, 8 smooth and 92 were not specified. 
For non-mass lesions, BIRADS type of enhancement among the 65 benign non-masses 
included 15 focal (2 heterogeneous, 1 Clumped), 24 linear (6 clumped and 1 
heterogeneous), 1 regional (clumped), 2 segmental (1 homogeneous), and 1 ductal (1 
heterogeneous) distribution and architecture respectively (22 not specified). Among the 
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64 non-mass malignant lesions 9 were focal (2 heterogeneous), 19 linear (6 clumped, 1 
heterogeneous), 4 regional, 12 segmental (2 clumped, 1 heterogeneous, 2 stippled or 
punctuate), 3 ductal (2 clumped, 1 heterogeneous) and 17 were not specified. 
Feature Relevance and optimal subset selection: 
9 kinetic features were relevant for both the mass and non-mass lesions. For 
morphological features, circularity and irregularity were only relevant among masses, 
while the standard deviation of edge sharpness was only relevant among non-masses. 
For texture features, eight were relevant for masses and three different texture 
properties for non-masses. The majority of relevant features in each group were not 
relevant in the other (Fig 3). 18 out of 27 relevant features for masses, and 8 out of 17 
relevant features for non-masses, had statistically significant different z-scores (p-value 
< 0.001). The proportion of dynamic, morphological, and texture features that were 
relevant or tentative for each lesion group is shown in Table 2. 12 out of the 20 
dispersion features were relevant and 5 of out 20 were tentative for differentiating 
between mass and non-mass lesions. 
Performance comparison of classifier designs: 
Tables 3 and 4 summarize the AUC, sensitivity and specificity of 5 separately trained 
classifiers. The multiclass classifier achieved the lowest performance on the cross-
validation testing sets, followed by one-shot all benign vs. malignant classifier. Each of 
the three binary classifiers composing the cascade (i.e stage 1, stage 2 mass, stage 2 
non-mass) achieved comparable performances. Fig. 5 shows the AUC achieved by the 
individual binary classifiers on the test sets during the 10-fold cross-validation. 
Resampling-based differences in median AUC was 6.5% (p-value<0.001) higher for 
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binary mass than for one-shot, and 8.9% (p-value<0.001) higher for binary non-mass 
than for one-shot.  
Stage 1 and stage 2 classifier results in all available data were pooled to compare the 
performance of cascading classifiers with respect to one-shot. We sampled paired 
posterior probabilities produced by the one-shot and the cascade final ensemble of 
trees for predicting malignant versus benign lesion classification. The achieved ROC 
AUC was 0.91, 95%CI: [0.88-0.94] for cascading, in comparison to 0.89, 95%CI: [0.85-
0.92] for one-shot (Fig. 6). The median difference in AUC was 2% (p-value=0.0027).  
Analysis of misclassification rate: 
Of the 409 lesions in the study, 337 lesions were correctly classified by cascading 
classifiers, while only 327 lesions were correctly classified by one-shot. The difference 
in misclassified lesions was 10 cases, (72/409) missed by cascade versus (82/409) 
missed by one-shot or equivalently misclassified cases were reduced by 12.2%. 28 
cases were missed by both classifiers consisting of 13 benign, 6 malignant masses, and 
of 4 malignant and 5 benign non-masses. 44 lesions were missed by cascade but not 
by one-shot, and 54 were missed by one-shot but not by cascade. Mislabelling of 
mass/non-mass in stage 1, followed by correct malignancy prediction in stage 2, was 
more common among non-mass lesions (15 total non-mass and 1 mass lesions). A 
correct stage 2 classification of malignant or benign is possible despite an incorrect 
classification of mass/non-mass on stage 1. However, the analysis of misclassifications 
by stages revealed that the majority of misclassifications by cascading are due to 
second stage only misclassification (68/72) compared to first stage misclassification 
(4/72). Therefore, data shows that correctly labeling a lesion as mass/non-mass on 
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stage 1 has a better chance of predicting a correct malignancy on stage 2, in contrast to 
one-shot classifier which does not differentiate between mass and non-mass lesions. 
3. Discussion 
An optimal CAD system for breast MRI can benefit from differentiating between mass 
and non-mass lesions, in particular, when differences in computer extractable 
information from DCE-MRI reflect differences in tumor biology. In this work we 
investigated whether we can obtain an increase in discriminatory capability for the 
classification task of benign and malignant cases by differentiating between mass and 
non-mass types of enhancement. We were able to achieve a more accurate 
classification of malignant or benign (AUC=0.91) by using different features for 
mass and non-mass lesions. We obtained the best performance for a cascading 2-
stage classifier in comparison with the more traditional one-shot CAD classifier design. 
Separately training two distinct classifiers, one for mass and one for non-mass lesions, 
and using them in a cascade arrangement produced better results than using only one-
shot classifier, which does not differentiate between mass and non-mass lesions. This 
finding suggests that there is a beneficial effect of cascading and that mass/non-mass 
enhancement differentiation has a positive impact on the final misdiagnosis rate 
(decreases by 12%). Features used in the present study were chosen to include 
features used in traditional CAD one-shot studies (i.e dynamic, morphology and 
texture). We introduced dispersion features to differentiate between mass and non-
mass groups. In this context, cascading classifiers offer the advantage to further exploit 
differences in lesion groups in future studies, such as allowing the design of new 
features intended only for mass and non-mass.  
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Prior studies have reported similar CAD performances. Agliozzo et al. (18) used mass 
lesions only, training and validation sets of 54 malignant and 19 benign lesions and 
achieved a support vector machine (SVM) mean AUC of 0.96, when combining two 
morphological, one kinetic and two spatiotemporal features. Huang et al. (19) proposed 
3D morphological features, and using a training and validation set of 51 malignant and 
44 benign mass lesions achieved an AUC of 0.89 when combining 3D morphology and 
tumor shape features. However, neither study evaluated generalization performance on 
non-mass lesions.  
Gubern-Mérida et al. (20) proposed a CAD system to automatically locate lesions and 
used 55 mass, 50 non-mass malignant lesions and 114 normal screening cases in their 
study. The best achieved sensitivities were 0.96 for masses and 0.92 for non-masses 
per 7 FPs/case. Since this was a CAD-detection study, cases with benign pathology but 
BIRADS > 2 were excluded. In our study we report the diagnostic accuracy of our CAD 
system for the task of discriminating between malignant and benign lesions in cases 
that warranted biopsy at the time of imaging. Therefore, it is not possible to compare our 
results to (20) directly.  
Our study has some limitations. All images were acquired at a single site, mostly using 
a single protocol. Future testing on multi-institutional data and on varying scan protocols 
will be needed to determine whether the trained classifier is generalizable. Also, normal 
screening studies, not recalled for further diagnostic evaluation, were not considered 
and therefore we did not assess the system in a screening setting. Instead, this 
retrospective study focused on training a CAD system to better characterize suspicious 
lesions in MRI, presenting as a mass or non-mass enhancements. However, our results 
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are promising and suggest that a two stage classifier performs better than a one-shot 
classifier. This supports the idea that different proportions of morphological and textural 
features are specific for mass or non-mass lesions, and that a classifier trained to 
exclusively differentiate patterns of malignancy on each of these groups will produce the 
best diagnostic performance. In some cases the correct malignant/benign label was 
assigned by the cascade classifier even though the initial mass/non-mass classification 
was incorrect. It is possible that some non-mass lesions exhibit more mass like features 
and vice versa. In this study, the second stage classifier was trained using sets of mass 
and non-mass lesions selected according to the radiologists’ reports. Instead, one could 
train the second stage classifiers using the predictions made by the first stage as labels, 
i.e in a semi-supervised fashion, which could further maximize the strengths of 
cascading classifiers, as the classifier could learn to adapt dynamically to the computer-
based characterization of lesions. 
The inclusion of normal screening studies (BIRADS 1, 2, or 3) to assess CAD 
performance in a more realistic screening setting is matter of future work. This requires 
the use of a fully automated pipeline to segment MRI lesions, and a detection 
framework to reduce false-positive findings. In addition, other MRI modalities can also 
be investigated. For example diffusion-weighted imaging (DWI) is being used to resolve 
the presence of invasive components in DCIS using the apparent diffusion coefficient 
(ADC)(21), or to study the diffusion direction with diffusion tensor imaging (DTI). 
Although initial results are promising and it has been reported that lesions in contrast to 
normal parenchyma exhibit no predominant diffusivity direction, and that fractional 
anisotropy (FA) was significantly lower in benign compared to malignant lesions (22).  
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In conclusion, this study demonstrates a superior performance for malignant and benign 
CAD diagnosis of lesions by discriminating between mass and non-mass groups using 
a cascade arrangement of classifiers.  
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Table 1. Ground-truth pathology summarized by masses and non-masses. 
 
Feature type One-shot 
Stage 1: 
mass vs. non-mass 
Stage 2:  
binary mass 
Stage 2: binary 
non-mass 
Dynamic 59% (27/46) 35% (11/31) 65% (24/37) 62% (13/21) 
Morphology 11% (5/46) 3% (1/31) 8% (3/37) 24% (5/21) 
Texture 30% (14/46) 23% (7/31) 27% (10/37) 14% (3/21) 
Dispersion --- 39% (12/31) --- --- 
Table 2. Proportion of relevant and tentative selected subsets of features by type: 
dynamic, morphology, texture or dispersion (only used for stage1 mass vs. non-mass). 
 
 
 
Ground-truth pathology Masses Non-masses Total 
Benign 136 65 201 
Benign breast parenchyma 26 21 48 
Atypical Ductal Hyperplasia 5 11 16 
Atypical Lobular Hyperplasia 8 4 12 
In-situ Lobular Carcinoma 1 0 1 
Ductal Hyperplasia without Atypia 6 6 12 
Cysts 6 0 6 
Duct Papilloma 10 2 12 
Atypical Papilloma 2 1 3 
Fibrocystic 27 12 39 
Fibrosis 5 5 10 
Fibroadenoma 31 2 33 
Sclerosing Adenosis 5 1 6 
Dystrophic Calcification 1 0 1 
Phyllodes tumor 1 0 1 
Radial scar 1 0 1 
Malignant 144 64 208 
In-situ Ductal Carcinoma 30 26 56 
In-situ papillary Carcinoma 1 1 2 
Invasive Ductal Carcinoma 96 29 125 
Invasive Lobular Carcinoma 16 6 22 
Metaplastic Carcinoma 1 0 1 
Adenocarcinoma 1 1 2 
Total 280 129 409 
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cv. test 
performance 
Multi-class average  
One-shot  
all benign vs. malignant 
AUC 0.67 IQR: 0.63-0.73 0.83 IQR: 0.81-0.85 
Sensitivity 0.43 IQR: 0.375-0.625 0.76 IQR: 0.65-0.81 
Specificity 0.75 IQR: 0.71-0.83 0.75 IQR: 0.7-0.8 
Table 3. Cross-validation performance of classifier designs compared on hold-out test 
sets achieved during 10-fold cross-validation. 
 
Cascading  
cv. test 
performance 
Stage 1 Stage 2 mass Stage 2 non-mass 
Binary  
mass vs. non-mass 
Binary mass  
Benign vs. malignant 
Binary non-mass  
Benign vs. malignant 
AUC 0.87 IQR: 0.82-0.88 0.89 IQR: 0.87-0.89 0.92 IQR: 0.83-0.95 
Sensitivity 0.95 IQR: 0.95-1 0.86 IQR: 0.86-0.875 1.00 IQR: 0.64-1 
Specificity 0.7 IQR: 0.45-0.95 0.77 IQR: 0.69-0.92 0.57 IQR: 0.43-1 
Table 4. Classifier performance of cascade classifiers on hold-out test sets achieved 
during 10-fold cross-validation.  
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Figure legends 
1 DCE-MRI of a 58-year-old woman with an invasive ducal carcinoma appearing at 
a mass lesion in the right breast. Patient undergoing high risk screening 
imaging. Lesion BIRADS 4, recalled for US guided core needle biopsy. a) 1st 
post-contract b) 2nd post contrast c) 3rd post-contrast d) 4th post-contrast, 
magnified view of segmented lesion is shown. 
 
 
2 DCE-MRI of a 47-year-old woman with an in-situ ducal carcinoma appearing as a 
non-mass lesion in the left breast. Patient undergoing follow-up imaging after 
Atypical ductal hyperplasia found in the right breast. Lesion BIRADS 4, recalled 
for stereotactic core needle biopsy. a) 1st post-contract b) 2nd post contrast c) 3rd 
post-contrast d) 4th post-contrast, magnified view of segmented lesion is shown. 
  
 
3 Comparison of Z-scores for relevant mass and non-mass features. a) Commonly 
relevant for both mass and non-mass lesions (statistically non-significantly 
different Z-scores). b)  Only relevant for masses c) Only relevant for non-
masses.  Abbrv. SE=Signal enhancement, SER=Signal enhancement ratio, 
Tpeak=Time-to-peak, Cr=Contrast, std=Standard deviation. 
 
 
4 AUC from cv.test performance for selected tree ensembles. 
 
 
5 Performance comparison. ROC plot for comparing cascade vs. one-shot 
classifier 
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Appendix 1. 
 
 
 
 
 
 
Imaging protocols used in our institution. Abbrv: NPW: No Phase Wrap, VB: Variable 
Bandwidth, MPh: Multi-Phase 
 
Protocol 
Bilateral  
3D DCE-MRI  
Bilateral Patched 
3D DCE-MRI 
Bilateral  
2D DCE-MRI 
Number of lesions 397 9 3 
plane Saggital Saggital Saggital 
Pulse sequence 3D SPGR 3D SPGR 2D SPGR 
SCAN TIMING 
Flip angle 15 40 50 
TE Min Full 4.3 4.2 
ACQUISITION TIMING 
Freq 288 256 256 
Phase 224 256 128 
NEX 1 1 1 
Freq DIR A/P A/P --- 
SCAN RANGE  
FOV 16 cm 18-20  cm 18-20  cm 
Slice thickness 3 mm 2 – 3 mm 4  mm 
ADDITIONAL PARAMETERS 
SAT FAT NONE FAT 
Options NPW, Fast, MPh VB, SQPIX Fast, VB,  MPh 
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 Reasons for imaging # lesions 
High risk MRI screening (n=233) 
Mutation carriers (e.g BRCA1/2, other genes) 37 
Family history 64 
Prior high risk marker 32 
Prior personal history 61 
Follow up recommended after previous MRI (BIRADS 0-3) 17 
Follow up after previous exam (other imaging) 22 
Non High risk screening (n=176) 
Further evaluation after other imaging 104 
Pre-operative extent of disease 52 
Problem solving imaging 17 
Pre-neoadjuvant treatment 2 
Prior to prophylactic mastectomy 1 
Total 409 
 
Reasons for breast MRI examination.  
 
 
 
 
 
 
 
Histo-pathology by radiology procedure type or surgery. 
Radiology procedure type and guidance localization 
Core Needle Biopsy Vacuum Assisted Biopsy Fine Needle Aspiration 
Guidance  
localization 
MRI 11 MRI 91 US 13 
Stereo 37 Stereo 1 Stereo 2 
US 151   N/A 2 
N/A 22     
TOTAL 221  92  17 
Not Specified    16 Surgery 63 
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DCE-MRI of a 58-year-old woman with an invasive ducal carcinoma appearing at a mass lesion in the right 
breast. Patient undergoing high risk screening imaging. Lesion BIRADS 4, recalled for US guided core needle 
biopsy. a) 1st post-contract b) 2nd post contrast c) 3rd post-contrast d) 4th post-contrast, magnified view 
of segmented lesion is shown.  
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DCE-MRI of a 58-year-old woman with an invasive ducal carcinoma appearing at a mass lesion in the right 
breast. Patient undergoing high risk screening imaging. Lesion BIRADS 4, recalled for US guided core needle 
biopsy. a) 1st post-contract b) 2nd post contrast c) 3rd post-contrast d) 4th post-contrast, magnified view 
of segmented lesion is shown.  
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DCE-MRI of a 58-year-old woman with an invasive ducal carcinoma appearing at a mass lesion in the right 
breast. Patient undergoing high risk screening imaging. Lesion BIRADS 4, recalled for US guided core needle 
biopsy. a) 1st post-contract b) 2nd post contrast c) 3rd post-contrast d) 4th post-contrast, magnified view 
of segmented lesion is shown.  
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DCE-MRI of a 58-year-old woman with an invasive ducal carcinoma appearing at a mass lesion in the right 
breast. Patient undergoing high risk screening imaging. Lesion BIRADS 4, recalled for US guided core needle 
biopsy. a) 1st post-contract b) 2nd post contrast c) 3rd post-contrast d) 4th post-contrast, magnified view 
of segmented lesion is shown.  
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DCE-MRI of a 47-year-old woman with an in-situ ducal carcinoma appearing as a non-mass lesion in the left 
breast. Patient undergoing follow-up imaging after Atypical ductal hyperplasia found in the right breast. 
Lesion BIRADS 4, recalled for stereotactic core needle biopsy. a) 1st post-contract b) 2nd post contrast c) 
3rd post-contrast d) 4th post-contrast, magnified view of segmented lesion is shown.  
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DCE-MRI of a 47-year-old woman with an in-situ ducal carcinoma appearing as a non-mass lesion in the left 
breast. Patient undergoing follow-up imaging after Atypical ductal hyperplasia found in the right breast. 
Lesion BIRADS 4, recalled for stereotactic core needle biopsy. a) 1st post-contract b) 2nd post contrast c) 
3rd post-contrast d) 4th post-contrast, magnified view of segmented lesion is shown.  
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DCE-MRI of a 47-year-old woman with an in-situ ducal carcinoma appearing as a non-mass lesion in the left 
breast. Patient undergoing follow-up imaging after Atypical ductal hyperplasia found in the right breast. 
Lesion BIRADS 4, recalled for stereotactic core needle biopsy. a) 1st post-contract b) 2nd post contrast c) 
3rd post-contrast d) 4th post-contrast, magnified view of segmented lesion is shown.  
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DCE-MRI of a 47-year-old woman with an in-situ ducal carcinoma appearing as a non-mass lesion in the left 
breast. Patient undergoing follow-up imaging after Atypical ductal hyperplasia found in the right breast. 
Lesion BIRADS 4, recalled for stereotactic core needle biopsy. a) 1st post-contract b) 2nd post contrast c) 
3rd post-contrast d) 4th post-contrast, magnified view of segmented lesion is shown.  
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Comparison of Z-scores for relevant mass and non-mass features. a) Commonly relevant for both mass and 
non-mass lesions (statistically non-significantly different Z-scores). b)  Only relevant for masses c) Only 
relevant for non-masses.  Abbrv. SE=Signal enhancement, SER=Signal enhancement ratio, Tpeak=Time-to-
peak, Cr=Contrast, std=Standard deviation.  
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AUC from cv.test performance for selected tree ensembles.  
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Performance comparison. ROC plot for comparing cascade vs. one-shot classifier  
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